LEVOFLOXACIN (TAVANIC) IN THE TREATMENT OF PNEUMONIA

The article is dedicated to the problems of diagnosis of pneumonia from the standpoint of evidence-based medicine. Data for the etiologic agents of pneumonia and the spectrum of action of levofloxacin (tavanic) are presented. Features of the bioavailability and pharmacokinetics allow to apply this drug once a day that provides high treatment compliance. Administration of tavanic for the treatment of more than 400 patients with pneumonia in a pulmonary unit have shown that the drug is highly effective and well tolerated. The criteria of application of tavanic, different dosage regimens for pneumonias of varying severity are considered. The schemes of administration of tavanic as step monotherapy and in the treatment of critically serious patients are presented.

community-acquired pneumonia, nosocomial pneumonia, antibiotic therapy, respiratory fluoroquinolones, levofloxacin, tavanic